There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical patients treated with perioperative nivolumab (Opdivo) and chemotherapy ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

Chemotherapy and immunotherapy followed by de-escalated chemoradiation showed increased survival and reduced side effects in aggressive head and neck cancers that are not associated with human ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Patients with resectable HNSCC were randomized to one of three neoadjuvant strategies: single-agent nivolumab, nivolumab/ipilimumab, or nivolumab/relatlimab. They categorized pTR by extent of ...